Timothy Mills, Ph.D.
Managing Director

Timothy Mills has over twenty-five years of experience in biomedical research, corporate management and venture investing. Dr. Mills joined Sanderling as an Operating Partner in July 1998, and was promoted to Managing Director in 2000. At Sanderling, Dr. Mills has focused on early stage investments in Medical Devices, Biotherapeutics, and i-Health. He has served Sanderling’s portfolio companies as Chairman, Chief Executive Officer, Director, and or management team member. Portfolio companies served include Stereotaxis (NASDAQ: STXS) and Stentor, acquired by Royal Philips Electronics (NYSE: PHG, AEX: PHI), CardioNet (NASDAQ: BEAT). Currently, his services include Chairman and or CEO of Torax Medical, Taligen Therapeutics, Pulsar Vascular, Theregen and Director for Naviscan, Novostent, InfraReDx, TriageWireless and others.

Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific (NYSE: BSX) in 1997. From July 1994 to July 1997, he was a director for Prograft Medical, a Target affiliate that was acquired by W.L Gore & Associates.

Prior to joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare, now Edwards Life Science (NYSE: EW). Dr. Mills' previous academic appointments included service as the Director of the Artificial Heart Program at the University of California, Irvine Medical Center and membership in the University of California, San Francisco Radiology Department.

Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine, his M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and his B.S. in Electrical Engineering from the University of Colorado, Boulder.